StockData
Radiopharm Theranostics Ltd logo

Radiopharm Theranostics Ltd (RADX) stock

RADXNasdaqPharmaceutical PreparationsFiscal year ends June 30Also trades as RDPTF
Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Sep 30, 2026Score 6/30
$0.76−0.03 (-3.80%)

Close on Nov 13, 2026Market cap $8.98MP/E –Yield –

Earnings

Radiopharm Theranostics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
–
Not yet scheduled
Revenue
–
EPS
–
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Radiopharm Theranostics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Radiopharm Theranostics has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Radiopharm Theranostics puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Radiopharm Theranostics filed with the SEC as exhibits to Form 8-K or 6-K

  1. CHANGE OF DIRECTOR'S INTEREST NOTICES X 4
    6-K
  2. QUARTERLY ACTIVITIES/APPENDIX 4C CASH FLOW REPORT
    6-K
  3. NOTICE OF ANNUAL GENERAL MEETING/PROXY FORM
    6-K
  4. RADIOPHARM RECEIVES $8M ADVANCE ON FY26 R&D TAX INCENTIVE
    6-K
  5. CHANGE OF DIRECTOR'S INTEREST NOTICES X 4
    6-K
  6. NOTIFICATION REGARDING UNQUOTED SECURITIES - RAD
    6-K
  7. RAD COMPLETES MEETING WITH US FDA FOR DEVELOPMENT OF RAD101
    6-K
  8. CHANGE OF DIRECTOR'S INTEREST NOTICE (RC)
    6-K
  9. NOTIFICATION OF CESSATION OF SECURITIES - RAD
    6-K
  10. APPENDIX 4G AND CORPORATE GOVERNANCE STATEMENT
    6-K
  11. CHANGE OF DIRECTOR'S INTEREST NOTICES X 4
    6-K
  12. RAD ORAL PRESENTATION AT SNO26 ON RAD101 PHASE IIB DATA
    6-K
  13. Australia – Friday, 11 September 2026 – Radiopharm Theranostics Limited (ASX: RAD; Nasdaq: RADX) advises that all
    6-K
  14. RAD ANNOUNCES POSITIVE DATA FROM RAD301 P1 IMAGING TRIAL
    6-K
  15. APPENDIX 4E AND PRELIMINARY FINAL REPORT
    6-K

See a number that looks wrong?